S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
Fed's Shocking New Plan to Control Your Money (Ad)
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
BREAKING: Tiny biotech successfully treats blindness (Ad)
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
Fed's Shocking New Plan to Control Your Money (Ad)
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
BREAKING: Tiny biotech successfully treats blindness (Ad)
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
Fed's Shocking New Plan to Control Your Money (Ad)
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
BREAKING: Tiny biotech successfully treats blindness (Ad)
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
S&P 500   4,027.81
DOW   32,717.60
QQQ   312.72
3 Undervalued Dividend Payers For Volatile Market Conditions
Fed's Shocking New Plan to Control Your Money (Ad)
3 More Downgrades To Put On Your Buy List 
Three Pullback Opportunities in Tech Right Now
BREAKING: Tiny biotech successfully treats blindness (Ad)
Three Mid Caps Wall Street Sees Doubling Within 12 Months
The Most Important Warren Buffett Stock for Investors: His Own
BREAKING: Tiny biotech successfully treats blindness (Ad)
Dave & Buster’s Rebound Could Score for Investors 
Micron Technology Goes on Breakout Watch
NASDAQ:HSKA

Heska - HSKA Stock Forecast, Price & News

$94.40
+1.09 (+1.17%)
(As of 03/29/2023 12:00 AM ET)
Add
Compare
Today's Range
$93.46
$95.20
50-Day Range
$79.87
$94.40
52-Week Range
$57.83
$149.17
Volume
133,675 shs
Average Volume
125,075 shs
Market Capitalization
$1.03 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$121.75

Heska MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
29.0% Upside
$121.75 Price Target
Short Interest
Bearish
5.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.76mentions of Heska in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$645,875 Bought Last Quarter
Proj. Earnings Growth
250.00%
From $0.30 to $1.05 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.37 out of 5 stars

Medical Sector

232nd out of 999 stocks

Diagnostic Substances Industry

4th out of 14 stocks


HSKA stock logo

About Heska (NASDAQ:HSKA) Stock

Heska Corp. engages in the provision of veterinary and animal health diagnostic, and specialty products. It operates through the North America and International segments. The North America segment includes the United States, Canada, and Mexico. The International segment involves Australia, France, Germany, Italy, Malaysia, Spain, and Switzerland. The company was founded by Robert B. Grieve and Lynnor B. Stevenson in 1988 and is headquartered in Loveland, CO.

Receive HSKA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heska and its competitors with MarketBeat's FREE daily newsletter.

HSKA Stock News Headlines

Here’s Your Own Billion-Dollar Trading Edge (Just $0.76 a Week)
2023 is a classic “stock picker’s market.” The only way to beat these markets is to pick the right stocks at the right time. Legendary trader Adam Mesh is ready to hand you his best stock pick every week… It’s the same kind of research Wall Street’s top traders use to beat the markets. Click here to get his three top picks for right now to help get you started now. pixel
Heska (HSKA) Moves to Buy: Rationale Behind the Upgrade
Here’s Your Own Billion-Dollar Trading Edge (Just $0.76 a Week)
2023 is a classic “stock picker’s market.” The only way to beat these markets is to pick the right stocks at the right time. Legendary trader Adam Mesh is ready to hand you his best stock pick every week… It’s the same kind of research Wall Street’s top traders use to beat the markets. Click here to get his three top picks for right now to help get you started now. pixel
Heska (HSKA) Moves 9.0% Higher: Will This Strength Last?
Heska Corporation Reports Third Quarter 2022 Results
Heska (HSKA) Q3 Earnings and Revenues Lag Estimates
See More Headlines
Receive HSKA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Heska and its competitors with MarketBeat's FREE daily newsletter.

HSKA Company Calendar

Last Earnings
11/04/2021
Today
3/29/2023
Next Earnings (Estimated)
5/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HSKA
Employees
655
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$121.75
High Stock Price Forecast
$150.00
Low Stock Price Forecast
$58.00
Forecasted Upside/Downside
+29.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-19,890,000.00
Pretax Margin
-8.49%

Debt

Sales & Book Value

Annual Sales
$257.31 million
Cash Flow
$1.73 per share
Book Value
$39.00 per share

Miscellaneous

Free Float
9,676,000
Market Cap
$1.03 billion
Optionable
Not Optionable
Beta
1.53

Key Executives

  • Kevin S. WilsonKevin S. Wilson
    President, Chief Executive Officer & Director
  • Nancy Wisnewski
    Chief Operating Officer & Executive Vice President
  • Catherine I. GrassmanCatherine I. Grassman
    Chief Financial Officer & Executive Vice President
  • Glenn R. Frank
    Vice President-Research & Development
  • Steven M. Eyl
    Chief Commercial Officer & Executive VP













HSKA Stock - Frequently Asked Questions

Should I buy or sell Heska stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Heska in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HSKA shares.
View HSKA analyst ratings
or view top-rated stocks.

What is Heska's stock price forecast for 2023?

4 Wall Street research analysts have issued 12-month price objectives for Heska's stock. Their HSKA share price forecasts range from $58.00 to $150.00. On average, they predict the company's share price to reach $121.75 in the next twelve months. This suggests a possible upside of 29.0% from the stock's current price.
View analysts price targets for HSKA
or view top-rated stocks among Wall Street analysts.

How have HSKA shares performed in 2023?

Heska's stock was trading at $62.16 at the beginning of 2023. Since then, HSKA stock has increased by 51.9% and is now trading at $94.40.
View the best growth stocks for 2023 here
.

When is Heska's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our HSKA earnings forecast
.

How were Heska's earnings last quarter?

Heska Co. (NASDAQ:HSKA) issued its earnings results on Thursday, November, 4th. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by $0.23. The medical research company earned $60.24 million during the quarter, compared to analysts' expectations of $63.80 million. Heska had a positive trailing twelve-month return on equity of 0.57% and a negative net margin of 7.73%. Heska's revenue was up 6.4% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.25) EPS.

What guidance has Heska issued on next quarter's earnings?

Heska updated its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $278.00 million-$288.00 million, compared to the consensus revenue estimate of $278.56 million.

What is Kevin S. Wilson's approval rating as Heska's CEO?

5 employees have rated Heska Chief Executive Officer Kevin S. Wilson on Glassdoor.com. Kevin S. Wilson has an approval rating of 57% among the company's employees. This puts Kevin S. Wilson in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Heska own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heska investors own include Gilead Sciences (GILD), Exxon Mobil (XOM), Netflix (NFLX), Biogen (BIIB), AbbVie (ABBV), Amgen (AMGN), Broadcom (AVGO), Alibaba Group (BABA), Exelixis (EXEL) and Merck & Co., Inc. (MRK).

What is Heska's stock symbol?

Heska trades on the NASDAQ under the ticker symbol "HSKA."

Who are Heska's major shareholders?

Heska's stock is owned by many different retail and institutional investors. Top institutional shareholders include Fred Alger Management LLC (4.96%), abrdn plc (3.70%), Riverbridge Partners LLC (2.92%), Bank of America Corp DE (2.29%), Dimensional Fund Advisors LP (2.20%) and TimesSquare Capital Management LLC (2.16%). Insiders that own company stock include Bonnie J Trowbridge, Catherine Grassman, Jason D Aroesty, Kevin S Wilson, Nancy Wisnewski and Sharon J Larson.
View institutional ownership trends
.

How do I buy shares of Heska?

Shares of HSKA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Heska's stock price today?

One share of HSKA stock can currently be purchased for approximately $94.40.

How much money does Heska make?

Heska (NASDAQ:HSKA) has a market capitalization of $1.03 billion and generates $257.31 million in revenue each year. The medical research company earns $-19,890,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.

How many employees does Heska have?

The company employs 655 workers across the globe.

How can I contact Heska?

Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The official website for the company is www.heska.com. The medical research company can be reached via phone at (970) 493-7272, via email at investorrelations@heska.com, or via fax at 970-619-3003.

This page (NASDAQ:HSKA) was last updated on 3/30/2023 by MarketBeat.com Staff